Glucagon-like peptide 1 receptor (GLP1R) agonists, such as exendin-4, potentiate glucose-stimulated insulin secretion and are currently used in the management of type 2 diabetes. Interestingly, GLP1R agonists also have the ability to augment β-cell mass. In this report, we provide evidence that in the presence of glucose, exendin-4 stimulates rodent islet cell DNA replication via the activation of ribosomal protein S6 kinase 1 (S6K1) and that this is mediated by the protein kinase B (PKB)-dependent activation of mTOR complex 1 (mTORC1). We show that activation of this pathway is caused by the autocrine or paracrine activation of the IGF1 receptor (IGF1R), as siRNA-mediated knockdown of the IGF1R effectively blocked exendin-4-stimulated PKB ...
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neop...
A reduction in -cell mass is an important causative factor in type 1 and type 2 diabetes. Glucagon-l...
SummaryPerturbation of endoplasmic reticulum (ER) homeostasis impairs insulin biosynthesis, β cell s...
Glucagon-like peptide 1 receptor (GLP1R) agonists, such as exendin-4, potentiate glucosestimulated i...
Pharmacological long lasting Glucagon-like peptide-1 (GLP-1) analogues, such as Exendin-4, have beco...
Pharmacological long lasting Glucagon-like peptide-1 (GLP-1) analogues, such as Exendin-4, have bec...
Glucagon-like peptide-1 (GLP-1) promotes insulin secretion from pancreatic β-cells in a glucose dep...
Glucagon-like peptide 1 (GLP-1) augments glucose-stimulated insulin secretion (GSIS) through cAMP-in...
Glucagon-like peptide-1 (GLP-1) ameliorates the symptoms of diabetes through stimulation of insulin ...
Background/Aims: Prevention of diabetes requires maintenance of a functional beta-cell mass, the pos...
Inadequate pancreatic β cell function underlies type 1 and type 2 diabetes mellitus. Strategies to e...
Glucagon-like peptide-1 (GLP-1) controls glucose homeostasis by regulating secretion of insulin and ...
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activat...
Glucagon-like peptide-1 (GLP-1) protects beta-cells against apoptosis, increases their glucose compe...
Objective: Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diab...
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neop...
A reduction in -cell mass is an important causative factor in type 1 and type 2 diabetes. Glucagon-l...
SummaryPerturbation of endoplasmic reticulum (ER) homeostasis impairs insulin biosynthesis, β cell s...
Glucagon-like peptide 1 receptor (GLP1R) agonists, such as exendin-4, potentiate glucosestimulated i...
Pharmacological long lasting Glucagon-like peptide-1 (GLP-1) analogues, such as Exendin-4, have beco...
Pharmacological long lasting Glucagon-like peptide-1 (GLP-1) analogues, such as Exendin-4, have bec...
Glucagon-like peptide-1 (GLP-1) promotes insulin secretion from pancreatic β-cells in a glucose dep...
Glucagon-like peptide 1 (GLP-1) augments glucose-stimulated insulin secretion (GSIS) through cAMP-in...
Glucagon-like peptide-1 (GLP-1) ameliorates the symptoms of diabetes through stimulation of insulin ...
Background/Aims: Prevention of diabetes requires maintenance of a functional beta-cell mass, the pos...
Inadequate pancreatic β cell function underlies type 1 and type 2 diabetes mellitus. Strategies to e...
Glucagon-like peptide-1 (GLP-1) controls glucose homeostasis by regulating secretion of insulin and ...
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activat...
Glucagon-like peptide-1 (GLP-1) protects beta-cells against apoptosis, increases their glucose compe...
Objective: Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diab...
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neop...
A reduction in -cell mass is an important causative factor in type 1 and type 2 diabetes. Glucagon-l...
SummaryPerturbation of endoplasmic reticulum (ER) homeostasis impairs insulin biosynthesis, β cell s...